Related Experiment Video

Updated: Nov 23, 2025

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.7K

Preparation, COX-2 Inhibition and Anticancer Activity of Sclerotiorin Derivatives

Tao Chen1, Yun Huang2,3, Junxian Hong1

  • 1School of Chemistry, Guangzhou Key Laboratory of Analytical Chemistry for Biomedicine, South China Normal University, Guangzhou 510006, China.

Marine Drugs
|January 1, 2021
PubMed

Insights

New sclerotiorin derivatives show potent anti-cancer activity and cyclooxygenase-2 (COX-2) inhibition. Compound 3 demonstrated significant cytotoxic effects and strong COX-2 inhibition, suggesting potential as novel anti-tumor agents.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Cancer Research

Background:

  • Emerging research highlights the potential of anti-tumor agents with cyclooxygenase-2 (COX-2) inhibitory activity to enhance anti-tumor efficacy.
  • Sclerotiorin derivatives are being explored for their therapeutic potential in cancer treatment.

Purpose of the Study:

  • To synthesize and evaluate novel sclerotiorin derivatives for their cytotoxic activity against human lung (A549) and breast (MDA-MB-435) cancer cell lines.
  • To assess the in vitro cyclooxygenase-2 (COX-2) inhibitory activity of these synthesized compounds.
  • To investigate the structure-activity relationships (SARS) and rationalize their potential as COX-2 inhibitory agents using molecular docking.

Main Methods:

  • Synthesis of a series of sclerotiorin derivatives.
  • Cytotoxic activity screening using the MTT assay against A549 and MDA-MB-435 cancer cell lines.
  • In vitro evaluation of COX-2 inhibitory activity.
  • Molecular docking simulations to predict binding interactions with the COX-2 active site.

Main Results:

  • Compounds 3, 7, 12, 13, 15, and 17 exhibited significant cytotoxic activity with IC50 values ranging from 6.39 to 9.76 μM.
  • Compounds 7, 13, 25, and sclerotiorin demonstrated moderate to good COX-2 inhibition (51.1%–66.1%).
  • Compound 3 showed notable COX-2 inhibition (70.6%), comparable to the positive control indomethacin (78.9%).
  • Molecular docking studies provided insights into the binding modes and energies of the derivatives within the COX-2 active site.

Conclusions:

  • The synthesized sclerotiorin derivatives possess promising cytotoxic and COX-2 inhibitory properties.
  • Compound 3 is identified as a lead candidate with significant anti-cancer potential due to its potent cytotoxic and COX-2 inhibitory activities.
  • These findings support the development of sclerotiorin derivatives as novel therapeutic agents for cancer treatment, particularly those involving COX-2 pathways.
Keywords:
COX-2 inhibitioncytotoxic activitymolecular dockingsclerotiorin derivatives

More Related Videos

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula09:03

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

562
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
320